SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Hochberg M 2000 Preventing fractures in postmenopausal women with osteoporosis. A review of recent controlled trials of antiresorptive agents. Drugs Aging 17: 317330.
  • 2
    Black DM, Cummings SR, Karpf DB, Cauley JA, Thompson DE, Nevitt MC, Bauer DC, Genant HK, Haskell WL, Marcus R, Ott SM, Torner JC, Quandt SA, Reiss TF, Ensrud KE 1996 Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet 348: 15351541.
  • 3
    Cummings SR, Black DM, Thompson DE, Applegate WB, Barrett-Connor E, Musliner TA, Palermo L, Prineas R, Rubin SM, Scott JC, Vogt T, Wallace R, Yates AJ, LaCroix AZ 1998 Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: Results from the Fracture Intervention Trial. JAMA 280: 20772082.
  • 4
    Black DM, Thompson DE, Bauer DC, Ensrud K, Musliner T, Hochberg MC, Nevitt MC, Suryawanshi S, Cummings SR 2000 Fracture risk reduction with alendronate in women with osteoporosis: The Fracture Intervention Trial. FIT Research Group. J Clin Endocrinol Metab 85: 41184124.
  • 5
    Black DM, Reiss TF, Nevitt MC, Cauley J, Karpf D, Cummings SR 1993 Design of the Fracture Intervention Trial. Osteoporos Int 3 (Suppl 3): S29S39.
  • 6
    Looker AC, Wahner HW, Dunn WL, Calvo MS, Harris TB, Heyse SP, Johnston CC Jr, Lindsay RL 1995 Proximal femur bone mineral levels of US adults. Osteoporos Int 5: 389409.
  • 7
    Liberman UA, Weiss SR, Bröll J, Minne HW, Quan H, Bell NH, Rodriguez-Portales J, Downs RW Jr, Dequeker J, Favus M 1995 Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group. N Engl J Med 333: 14371443.
  • 8
    Seeley DG, Browner WS, Nevitt MC, Genant HK, Scott JC, Cummings SR 1991 Which fractures are associated with low appendicular bone mass in elderly women. The Study of Osteoporotic Fractures Research Group. Ann Intern Med 115: 837842.
  • 9
    Genant HK, Wu CY, van Kuijk C, Nevitt MC 1993 Vertebral fracture assessment using a semiquantitative technique. J Bone Miner Res 8: 11371148.
  • 10
    Holford TR 1980 The analysis of rates and of survivorship using log-linear models. Biometrics 36: 299305.
  • 11
    Laird N, Oliver D 1981 Covariance analysis of censored survival data using log-linear analysis techniques. J Am Stat Assoc 76: 231240.
  • 12
    Cox DR, Oakes DO 1984 Analysis of Survival Data, vol. 21. Chapman and Hall, CRC Press, Boca Raton, FL, USA.
  • 13
    Preston DL Lubin, Pierce DE 1993 Epicure User's Guide. HiroSoft International Corp., Seattle, WA, USA.
  • 14
    Montori VM, Guyatt GH 2001 Intention-to-treat principle. Can Med Assoc J 165: 13391341.
  • 15
    Ensrud KE, Lipschutz RC, Cauley JA, Seeley D, Nevitt MC, Scott J, Orwoll ES, Genant HK, Cummings SR 1997 Body size and hip fracture risk in older women: A prospective study. Study of Osteoporotic Fractures Research Group. Am J Med 103: 274280.
  • 16
    Kanis JA, Johnell O, Oden A, Sernbo I, Redlund-Johnell I, Dawson A, De Laet C, Jonsson B 2000 Long-term risk of osteoporotic fracture in Malmö. Osteoporos Int 11: 669674.
  • 17
    Harris ST, Watts NB, Genant HK, McKeever CD, Hangartner T, Keller M, Chesnut CH III, Brown J, Eriksen EF, Hoseyni MS, Axelrod DW, Miller PD 1999 Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: A randomized controlled trial. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. JAMA 282: 13441352.
  • 18
    Reginster J, Minne HW, Sorensen OH, Hooper M, Roux C, Brandi ML, Lund B, Ethgen D, Pack S, Roumagnac I, Eastell R 2000 Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. Osteoporos Int 11: 8391.
  • 19
    Watts NB, Josse RG, Hamdy RC, Hughes RA, Manhart MD, Barton I, Calligeros D, Felsenberg D 2003 Risedronate prevents new vertebral fractures in postmenopausal women at high risk. J Clin Endocrinol Metab 88: 542549.
  • 20
    McClung MR, Geusens P, Miller PD, Zippel H, Bensen WG, Roux C, Adami S, Fogelman I, Diamond T, Eastell R, Meunier PJ, Reginster JY 2001 Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group. N Engl J Med 344: 333340.